biotech
biotech Articles
Johnson &; Johnson, Gilead Sciences and Amicus Therapeutics are among companies expecting clinical trial and FDA updates in February.
Published:
Last Updated:
The January 12 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
Published:
Last Updated:
Puma Biotechnology saw its shares take a dive on Wednesday following regulatory events in Europe for its breast cancer treatment.
Published:
Last Updated:
Solid Biosciences intends to price its 7 million shares so that its initial public offering is valued up to nearly $153 million.
Published:
Last Updated:
Nymox Pharmaceutical watched its shares make a solid gain on Monday after the firm announced five-year results from its prostate cancer study.
Published:
Last Updated:
Bioverativ is adding to Monday’s M&A news after it was announced that Sanofi would be acquiring the firm.
Published:
Last Updated:
Juno Therapeutics saw its shares take off early on Monday after it was announced that Celgene would be acquiring it.
Published:
Last Updated:
Menlo Therapeutics plans on pricing its more than 5 million shares in a range that results in an initial public offering valued up to more than $104 million.
Published:
Last Updated:
Credit Suisse sees tax reform sparking a wave of mergers in the emerging pharmaceuticals space, which could produce sector outperformance. The firm is cautiously optimistic on this front.
Published:
Last Updated:
BeiGene saw its shares make a handy gain on Thursday after the company announced that it would be conducting a secondary offering.
Published:
Last Updated:
Shares of Exelixis slipped on Wednesday after the company reported results from its late-stage trial of cabozantinib for advanced hepatocellular carcinoma.
Published:
Last Updated:
ARMO BioSciences intends to price more than 6. million shares in a range that results in an initial public offering valued up to more than $122 million.
Published:
Last Updated:
Juno Therapeutics saw its shares skyrocket early on Wednesday after reports that Celgene was in talks to acquire the company.
Published:
Last Updated:
Eiger BioPharmaceuticals watched its shares crater on Tuesday after the firm announced that its midstage study in pulmonary arterial hypertension did not meet its primary endpoint.
Published:
Last Updated:
Solid Biosciences intends to price its less than 6 million shares in the range that results in an initial public offering valued up to almost $122 million.
Published:
Last Updated: